Something that comes up in blinded phase 3 obesity trials around week 32: the first 16 weeks appetite is basically gone, then hunger creeps back to roughly 70% of baseline — even while the tape measure and the labs keep moving the right way. Waist down 9 cm. Fasting glucose 92, down from 104. A1c 5.2, down from 5.7. Meanwhile the scale sits at -11.4 kg for three weeks without budging.
The part people forget is that the appetite rebound can show up before the next scheduled visit, and from the inside there's no way to tell whether it's the drug fading, a dose question, or just the maintenance phase settling in. Common surprise: trial coordinators mostly log it and say keep going — that's their job, not their call, so don't expect much interpretation there.
Worth knowing before comparing options or comparing notes: stalls at the same time as hunger returning is a pattern, not necessarily a problem. If that's happening in a blinded trial, it's a genuinely useful thing to compare against other people's timelines.